Resources for Interpreting Variants in Precision Genomic Oncology Applications
暂无分享,去创建一个
Hsinyi Tsang | KanakaDurga Addepalli | Sean R. Davis | Hsinyi Tsang | Sean R. Davis | Durga Addepalli | D. Addepalli
[1] Marilyn M. Li. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer , 2019 .
[2] Alok V. Joglekar,et al. Personalized T cell-mediated cancer immunotherapy: progress and challenges. , 2017, Current opinion in biotechnology.
[3] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[4] K. Garber. In a major shift, cancer drugs go 'tissue-agnostic'. , 2017, Science.
[5] Michael P. Schroeder,et al. Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations , 2017, Genome Medicine.
[6] Moriah H Nissan,et al. OncoKB: A Precision Oncology Knowledge Base. , 2017, JCO precision oncology.
[7] Lilia M. Iakoucheva,et al. MutPred2: inferring the molecular and phenotypic impact of amino acid variants , 2017, bioRxiv.
[8] Trevor J Pugh,et al. Data resources for the identification and interpretation of actionable mutations by clinicians , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] Levi Garraway,et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden , 2017, Genome Medicine.
[10] E. Jaffee,et al. Targeting neoantigens to augment antitumour immunity , 2017, Nature Reviews Cancer.
[11] Gavin R. Oliver,et al. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery , 2017, Oncotarget.
[12] Howard L. McLeod,et al. Key Lessons Learned from Moffitt's Molecular Tumor Board: The Clinical Genomics Action Committee Experience. , 2017, The oncologist.
[13] Steven J. M. Jones,et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer , 2017, Nature Genetics.
[14] Carrie Cibulskis,et al. Assigning clinical meaning to somatic and germ-line whole-exome sequencing data in a prospective cancer precision medicine study , 2017, Genetics in Medicine.
[15] Mingming Jia,et al. COSMIC: somatic cancer genetics at high-resolution , 2016, Nucleic Acids Res..
[16] Marcin Imielinski,et al. The cancer precision medicine knowledge base for structured clinical-grade mutations and interpretations , 2016, J. Am. Medical Informatics Assoc..
[17] Marilyn M. Li,et al. Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists. , 2017, The Journal of molecular diagnostics : JMD.
[18] Helen Y Wang,et al. Immune targets and neoantigens for cancer immunotherapy and precision medicine , 2016, Cell Research.
[19] Robert Gray,et al. NCI-Molecular Analysis for Therapy Choice (NCI-MATCH) trial: A novel public-private partnership , 2016 .
[20] Allison P. Heath,et al. Toward a Shared Vision for Cancer Genomic Data. , 2016, The New England journal of medicine.
[21] Obi L. Griffith,et al. CIViC: A knowledgebase for expert-crowdsourcing the clinical interpretation of variants in cancer , 2016, bioRxiv.
[22] Richard Simon,et al. Genomic AlterationDriven Clinical Trial Designs in Oncology , 2016, Annals of Internal Medicine.
[23] Marcin Imielinski,et al. The Precision Medicine Knowledge Base: an online application for collaborative editing, maintenance and sharing of structured clinical-grade cancer mutations interpretations , 2016, bioRxiv.
[24] Raymond Dalgleish,et al. HGVS Recommendations for the Description of Sequence Variants: 2016 Update , 2016, Human mutation.
[25] Benjamin S. Glicksberg,et al. Development and clinical application of an integrative genomic approach to personalized cancer therapy , 2016, Genome Medicine.
[26] Deanna M. Church,et al. A variant by any name: quantifying annotation discordance across tools and clinical databases , 2016, Genome Medicine.
[27] Obi L. Griffith,et al. High-performance web services for querying gene and variant annotation , 2016, Genome Biology.
[28] Jonathan R. Dry,et al. Defining actionable mutations for oncology therapeutic development , 2016, Nature Reviews Cancer.
[29] F. Cunningham,et al. The Ensembl Variant Effect Predictor , 2016, Genome Biology.
[30] Brent S. Pedersen,et al. Vcfanno: fast, flexible annotation of genetic variants , 2016, Genome Biology.
[31] E. Boerwinkle,et al. dbNSFP v3.0: A One‐Stop Database of Functional Predictions and Annotations for Human Nonsynonymous and Splice‐Site SNVs , 2016, Human mutation.
[32] M. Rubin,et al. Generating a neoantigen map of advanced urothelial carcinoma by whole exome sequencing. , 2016 .
[33] Ricardo Villamarín-Salomón,et al. ClinVar: public archive of interpretations of clinically relevant variants , 2015, Nucleic Acids Res..
[34] Deng Pan,et al. DGIdb 2.0: mining clinically relevant drug–gene interactions , 2015, Nucleic Acids Res..
[35] James Y. Zou. Analysis of protein-coding genetic variation in 60,706 humans , 2015, Nature.
[36] R. Pazdur,et al. Next-Generation Sequencing in Oncology in the Era of Precision Medicine. , 2016, JAMA oncology.
[37] A. Gonzalez-Perez,et al. Abstract A1-45: In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals novel targeting opportunities , 2015 .
[38] Steven J. M. Jones,et al. The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.
[39] William E. Evans,et al. Pharmacogenomics in the clinic , 2015, Nature.
[40] Hui Yang,et al. Genomic variant annotation and prioritization with ANNOVAR and wANNOVAR , 2015, Nature Protocols.
[41] Eliot Y. Zhu,et al. Cancer Driver Log (CanDL): Catalog of Potentially Actionable Cancer Mutations. , 2015, The Journal of molecular diagnostics : JMD.
[42] A. Gonzalez-Perez,et al. Abstract 2983: In silico prescription of anticancer drugs to cohorts of 28 tumor types reveals novel targeting opportunities , 2015 .
[43] Vladimir Vacic,et al. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response. , 2015, JAMA oncology.
[44] Gonçalo R. Abecasis,et al. Unified representation of genetic variants , 2015, Bioinform..
[45] B. Rost,et al. Better prediction of functional effects for sequence variants , 2015, BMC Genomics.
[46] Gary W Procop,et al. Prospective Clinical Study of Precision Oncology in Solid Tumors. , 2015, Journal of the National Cancer Institute.
[47] Donavan T. Cheng,et al. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology. , 2015, The Journal of molecular diagnostics : JMD.
[48] Trevor J Pugh,et al. Oncotator: Cancer Variant Annotation Tool , 2015, Human mutation.
[49] Udayan Guha,et al. Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[50] KanakaDurga Addepalli. Models Predicting Effects of Missense Mutations in Oncogenesis , 2014 .
[51] R. Tiu,et al. Practical management of patients with chronic myeloid leukemia who develop tyrosine kinase inhibitor-resistant BCR-ABL1 mutations , 2014, Therapeutic advances in hematology.
[52] A. Yenamandra,et al. Detection of Genomic Imbalances Involved in Common Chromosomal Rearrangements of Acute Leukemia by Cytogenomic SNP Microarray Analysis , 2014 .
[53] Jana Marie Schwarz,et al. MutationTaster2: mutation prediction for the deep-sequencing age , 2014, Nature Methods.
[54] J. Shendure,et al. A general framework for estimating the relative pathogenicity of human genetic variants , 2014, Nature Genetics.
[55] S. Gabriel,et al. Discovery and saturation analysis of cancer genes across 21 tumor types , 2014, Nature.
[56] G. Mills,et al. CanDrA: Cancer-Specific Driver Missense Mutation Annotation with Optimized Features , 2013, PloS one.
[57] Joshua F. McMichael,et al. DGIdb - Mining the druggable genome , 2013, Nature Methods.
[58] Michael P. Schroeder,et al. IntOGen-mutations identifies cancer drivers across tumor types , 2013, Nature Methods.
[59] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[60] Michael Thomas,et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. , 2013, The New England journal of medicine.
[61] Levi A Garraway,et al. Genomics-driven oncology: framework for an emerging paradigm. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[62] Bernd Hauck,et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. , 2013, The New England journal of medicine.
[63] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[64] I. Adzhubei,et al. Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2 , 2013, Current protocols in human genetics.
[65] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumours , 2013 .
[66] M. Eileen Dolan,et al. Cancer pharmacogenomics: strategies and challenges , 2012, Nature Reviews Genetics.
[67] K. Flaherty,et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. , 2012, The New England journal of medicine.
[68] J. Miller,et al. Predicting the Functional Effect of Amino Acid Substitutions and Indels , 2012, PloS one.
[69] Steven J. M. Jones,et al. Comprehensive molecular portraits of human breast tumors , 2012, Nature.
[70] Li Ding,et al. The Pediatric Cancer Genome Project , 2012, Nature Genetics.
[71] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[72] Pablo Cingolani,et al. © 2012 Landes Bioscience. Do not distribute. , 2022 .
[73] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[74] Fiona Cunningham,et al. A Combined Functional Annotation Score for Non-Synonymous Variants , 2012, Human Heredity.
[75] Syed Haider,et al. International Cancer Genome Consortium Data Portal—a one-stop shop for cancer genomics data , 2011, Database J. Biol. Databases Curation.
[76] C. Sander,et al. Predicting the functional impact of protein mutations: application to cancer genomics , 2011, Nucleic acids research.
[77] Gonçalo R. Abecasis,et al. The variant call format and VCFtools , 2011, Bioinform..
[78] A. Gonzalez-Perez,et al. Improving the assessment of the outcome of nonsynonymous SNVs with a consensus deleteriousness score, Condel. , 2011, American journal of human genetics.
[79] T. Mughal,et al. Principal long-term adverse effects of imatinib in patients with chronic myeloid leukemia in chronic phase , 2010, Biologics : targets & therapy.
[80] Serafim Batzoglou,et al. Identifying a High Fraction of the Human Genome to be under Selective Constraint Using GERP++ , 2010, PLoS Comput. Biol..
[81] Majid Masso,et al. AUTO-MUTE: web-based tools for predicting stability changes in proteins due to single amino acid replacements. , 2010, Protein engineering, design & selection : PEDS.
[82] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.
[83] A. Gemma,et al. F1000 highlights , 2010 .
[84] Robert B. Hartlage,et al. This PDF file includes: Materials and Methods , 2009 .
[85] K. Pollard,et al. Detection of nonneutral substitution rates on mammalian phylogenies. , 2010, Genome research.
[86] Leyla Isik,et al. Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. , 2009, Cancer research.
[87] E. Capriotti,et al. Functional annotations improve the predictive score of human disease‐related mutations in proteins , 2009, Human mutation.
[88] Gonçalo R. Abecasis,et al. The Sequence Alignment/Map format and SAMtools , 2009, Bioinform..
[89] S. Henikoff,et al. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm , 2009, Nature Protocols.
[90] Joshua M. Korn,et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.
[91] Valentin A. Ilyin,et al. Structure SNP (StSNP): a web server for mapping and modeling nsSNPs on protein structures with linkage to metabolic pathways , 2007, Nucleic Acids Res..
[92] R. Larson,et al. Long-term benefits of imatinib (IM) for patients newly diagnosed with chronic myelogenous leukemia in chronic phase (CML-CP): The 5-year update from the IRIS study. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] Peng Yue,et al. SNPs3D: Candidate gene and SNP selection for association studies , 2006, BMC Bioinformatics.
[94] G. Church,et al. The Personal Genome Project , 2005, Molecular systems biology.
[95] D. Haussler,et al. Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. , 2005, Genome research.
[96] Mi Zhou,et al. nsSNPAnalyzer: identifying disease-associated nonsynonymous single nucleotide polymorphisms , 2005, Nucleic Acids Res..
[97] M. Campbell,et al. PANTHER: a library of protein families and subfamilies indexed by function. , 2003, Genome research.
[98] Steven Henikoff,et al. SIFT: predicting amino acid changes that affect protein function , 2003, Nucleic Acids Res..
[99] Russ B. Altman,et al. PharmGKB: the Pharmacogenetics Knowledge Base , 2002, Nucleic Acids Res..
[100] Elizabeth M. Smigielski,et al. dbSNP: the NCBI database of genetic variation , 2001, Nucleic Acids Res..